X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs BIOCON LTD - Comparison Results

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA BIOCON LTD PLETHICO PHARMA/
BIOCON LTD
 
P/E (TTM) x -1.1 36.6 - View Chart
P/BV x 0.0 4.9 0.3% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 PLETHICO PHARMA   BIOCON LTD
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
BIOCON LTD
Mar-16
PLETHICO PHARMA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs395496 79.7%   
Low Rs31397 7.9%   
Sales per share (Unadj.) Rs604.4174.3 346.8%  
Earnings per share (Unadj.) Rs32.544.8 72.5%  
Cash flow per share (Unadj.) Rs51.356.9 90.2%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %01.1 0.0%  
Book value per share (Unadj.) Rs473.6202.8 233.5%  
Shares outstanding (eoy) m34.08200.00 17.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.42.6 13.8%   
Avg P/E ratio x6.610.0 65.9%  
P/CF ratio (eoy) x4.27.8 53.0%  
Price / Book Value ratio x0.52.2 20.5%  
Dividend payout %011.2 0.0%   
Avg Mkt Cap Rs m7,26289,220 8.1%   
No. of employees `000NA4.4 0.0%   
Total wages/salary Rs m1,5966,363 25.1%   
Avg. sales/employee Rs ThNM7,894.5-  
Avg. wages/employee Rs ThNM1,441.2-  
Avg. net profit/employee Rs ThNM2,029.7-  
INCOME DATA
Net Sales Rs m20,59834,854 59.1%  
Other income Rs m386845 45.7%   
Total revenues Rs m20,98435,699 58.8%   
Gross profit Rs m2,8188,200 34.4%  
Depreciation Rs m6422,423 26.5%   
Interest Rs m1,593102 1,562.0%   
Profit before tax Rs m9696,520 14.9%   
Minority Interest Rs m0-744 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m05,754 0.0%   
Tax Rs m-1382,569 -5.4%   
Profit after tax Rs m1,1078,961 12.4%  
Gross profit margin %13.723.5 58.1%  
Effective tax rate %-14.339.4 -36.3%   
Net profit margin %5.425.7 20.9%  
BALANCE SHEET DATA
Current assets Rs m18,87739,932 47.3%   
Current liabilities Rs m11,89616,276 73.1%   
Net working cap to sales %33.967.9 49.9%  
Current ratio x1.62.5 64.7%  
Inventory Days Days3654 67.1%  
Debtors Days Days19886 229.6%  
Net fixed assets Rs m9,86139,101 25.2%   
Share capital Rs m3411,000 34.1%   
"Free" reserves Rs m12,33138,591 32.0%   
Net worth Rs m16,13940,556 39.8%   
Long term debt Rs m4,70620,724 22.7%   
Total assets Rs m33,14684,816 39.1%  
Interest coverage x1.664.9 2.5%   
Debt to equity ratio x0.30.5 57.1%  
Sales to assets ratio x0.60.4 151.2%   
Return on assets %8.110.7 76.2%  
Return on equity %6.922.1 31.0%  
Return on capital %12.319.0 64.7%  
Exports to sales %21.430.7 69.5%   
Imports to sales %15.220.4 74.7%   
Exports (fob) Rs m4,40210,717 41.1%   
Imports (cif) Rs m3,1367,105 44.1%   
Fx inflow Rs m4,40211,789 37.3%   
Fx outflow Rs m3,1848,393 37.9%   
Net fx Rs m1,2193,396 35.9%   
CASH FLOW
From Operations Rs m2,4375,264 46.3%  
From Investments Rs m-6,265-9,540 65.7%  
From Financial Activity Rs m2,49010,867 22.9%  
Net Cashflow Rs m-1,3376,591 -20.3%  

Share Holding

Indian Promoters % 82.7 40.4 204.7%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.3 8.4 51.2%  
FIIs % 5.5 10.7 51.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 19.9 37.7%  
Shareholders   10,665 109,995 9.7%  
Pledged promoter(s) holding % 85.7 0.0 214,350.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA - TORRENT PHARMA COMPARISON

COMPARE PLETHICO PHARMA WITH

MARKET STATS